Xinjun Li1, Qingyuan Wang2, Limei Fu3, Min Liu3, Xuemei Yu3. 1. Department of Pathology, Binzhou People's Hospital, Binzhou Shandong 256610, China lixinjunhe@163.com. 2. Department of Science and Education, Binzhou People's Hospital, Binzhou Shandong 256610, China. 3. Department of Pathology, Binzhou People's Hospital, Binzhou Shandong 256610, China.
Abstract
OBJECTIVE: To study the expression of PTEN, p53 and epidermal growth factor receptor (EGFR) in the molecular subtypes of breast carcinoma and to evaluate the correlations with triple-negative breast cancer. METHODS: Immunohistochemical MaxVision(TM) method was used to detect the expression of PTEN, p53, EGFR, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in 291 cases of infiltrating ductal carcinoma of breast. RESULTS: The positive expression of PTEN, p53 and EGFR protein in breast carcinoma was 57.0%, 57.0% and 38.5%, respectively, which were significantly different from those in benign breast diseases (P<0.05). The expression of PTEN or EGFR in breast cancer was correlated with tumor size, histological grade, lymph node metastasis, TNM stage, ER and HER2 status (P<0.05); the expression of p53 was correlated with tumor size, histological grade and ER status (P<0.05). The difference of positive expression rates of PTEN, p53 and EGFR protein among different subtypes including luminal A, luminal B (HER2-), luminal B (HER2+), HER2 over-expression and triple-negative was statistically significant (P<0.05). There were close correlations among PTEN, p53 and EGFR in the triple-negative subtype (P<0.05). CONCLUSION: Low expression of PTEN and high expression of EGFR and p53 are observed in triple-negative breast cancer, which may synergistically contribute to the pathogenesis of triple-negative breast cancer.
OBJECTIVE: To study the expression of PTEN, p53 and epidermal growth factor receptor (EGFR) in the molecular subtypes of breast carcinoma and to evaluate the correlations with triple-negative breast cancer. METHODS: Immunohistochemical MaxVision(TM) method was used to detect the expression of PTEN, p53, EGFR, estrogen receptor (ER), progesterone receptor (PR) and humanepidermal growth factor receptor 2 (HER2) in 291 cases of infiltrating ductal carcinoma of breast. RESULTS: The positive expression of PTEN, p53 and EGFR protein in breast carcinoma was 57.0%, 57.0% and 38.5%, respectively, which were significantly different from those in benign breast diseases (P<0.05). The expression of PTEN or EGFR in breast cancer was correlated with tumor size, histological grade, lymph node metastasis, TNM stage, ER and HER2 status (P<0.05); the expression of p53 was correlated with tumor size, histological grade and ER status (P<0.05). The difference of positive expression rates of PTEN, p53 and EGFR protein among different subtypes including luminal A, luminal B (HER2-), luminal B (HER2+), HER2 over-expression and triple-negative was statistically significant (P<0.05). There were close correlations among PTEN, p53 and EGFR in the triple-negative subtype (P<0.05). CONCLUSION: Low expression of PTEN and high expression of EGFR and p53 are observed in triple-negative breast cancer, which may synergistically contribute to the pathogenesis of triple-negative breast cancer.
Authors: Luciano Izzo; Daniela Messineo; Pierfrancesco DI Cello; Virgilio Nicolanti; Antonio Sterpetti; Sara Izzo; Paolo Izzo Journal: In Vivo Date: 2021 Jan-Feb Impact factor: 2.155
Authors: Daphne Gschwantler-Kaulich; Yen Y Tan; Eva-Maria Fuchs; Gernot Hudelist; Wolfgang J Köstler; Angelika Reiner; Carmen Leser; Mohamed Salama; Johannes Attems; Christine Deutschmann; Christoph C Zielinski; Christian F Singer Journal: PLoS One Date: 2017-03-02 Impact factor: 3.240